K. Morrissey

发表

The UCSF‐FDA TransPortal: A Public Drug Transporter Database

K. Giacomini, K. Morrissey, C. Wen, 2012, Clinical pharmacology and therapeutics.

Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro

K. Giacomini, K. Morrissey, T. Tracy, 2010, Pharmacogenetics and genomics.

A Common 5′‐UTR Variant in MATE2‐K Is Associated With Poor Response to Metformin

J. Mefford, J. Witte, P. Kwok, 2011, Clinical pharmacology and therapeutics.

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2018, Breast Cancer Research.

A validated surrogate analyte LC-MS/MS assay for quantitation of endogenous kynurenine and tryptophan in human plasma.

K. Morrissey, S. Mahrus, Xiaorong Liang, 2018, Bioanalysis.

Expanding the Role of the Dynein Regulatory Complex to Non‐Axonemal Functions: Association of GAS11 with the Golgi Apparatus

K. Morrissey, K. Hill, R. Crosbie, 2006, Traffic.

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Jin Y. Jin, K. Morrissey, S. Girish, 2019, Cancer Chemotherapy and Pharmacology.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

K. Morrissey, F. Hodi, M. Ahn, 2019, Clinical Cancer Research.

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

J. Ware, K. Morrissey, L. Salphati, 2019, British journal of clinical pharmacology.

Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics

John D. Davis, J. Ware, K. Morrissey, 2017, CPT: pharmacometrics & systems pharmacology.

The Patient‐Centered Future of Clinical Pharmacology

Mohamed H. Shahin, K. Morrissey, Julie A. Johnson, 2019, Clinical pharmacology and therapeutics.

Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction

K. Morrissey, Magang Shou, Yang Xu, 2008, Drug Metabolism and Disposition.

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

John Kurhanewicz, Youcai Zhang, Kevan M. Shokat, 2014, Proceedings of the National Academy of Sciences.

Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.

Andrej Sali, Natalia Khuri, A. Sali, 2013, Journal of medicinal chemistry.

Renal transporters in drug development.

K. Giacomini, K. Morrissey, M. Wittwer, 2013, Annual review of pharmacology and toxicology.

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

K. Morrissey, D. Munn, C. Link, 2018, Journal of Immunotherapy for Cancer.

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2018, Breast Cancer Research.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

H. Groen, J. Ware, K. Morrissey, 2017, European Journal of Cancer.

Consequences of POR mutations and polymorphisms

K. Giacomini, K. Morrissey, W. Miller, 2011, Molecular and Cellular Endocrinology.

Discovery of Regulatory Elements in Human ATP-Binding Cassette Transporters through Expression Quantitative Trait Mapping

J. Xuan, K. Giacomini, S. Yee, 2011, The Pharmacogenomics Journal.

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

K. Morrissey, F. Hodi, P. LoRusso, 2017 .

The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin

C. McCarty, D. Roden, R. Wilke, 2013, Clinical pharmacology and therapeutics.

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

K. Morrissey, F. Cattaruzza, Milton To, 2023, Nature Cancer.

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

P. Wen, T. Cloughesy, T. Wilson, 2020, Clinical Cancer Research.

Abstract P5-19-10: Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2015 .

346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors

K. Morrissey, D. Munn, C. Link, 2015 .

Computational analysis of kinase inhibitor selectivity using structural knowledge

Russ B. Altman, Tianyun Liu, Yu Zhong, 2018, Bioinform..

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

J. Desai, Robert W. Hsieh, K. Morrissey, 2020 .

Genome-Wide Discovery of Drug-Dependent Human Liver Regulatory Elements

N. Trinklein, K. Giacomini, K. Morrissey, 2014, PLoS genetics.

The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers

K. Giacomini, K. Morrissey, R. Castro, 2016, Clinical Pharmacokinetics.

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

J. Kurhanewicz, K. Shokat, K. Giacomini, 2014, Proceedings of the National Academy of Sciences.

Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro

K. Giacomini, K. Morrissey, T. Tracy, 2010, Pharmacogenetics and genomics.